The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and newly approved agents and combination therapies.
In a small study, patients treated with romosozumab had a greater increase in spine bone mineral density, compared with the denosumab group after 1 year.
In the second-line setting of head and neck cancer, metronomic triple therapy outperformed clinician choice chemotherapy in both progression-free survival and overall survival.
Radiation therapy may be safely omitted for patients with primary mediastinal B-cell lymphoma (PMBCL) who achieved a complete metabolic response after immunochemotherapy.
The antibody-drug conjugate trastuzumab-deruxtecan was associated with high objective response rates among patients with a range of HER2-expressing solid tumors.